公开(公告)号：US20220378722A1

公开(公告)日：2022-12-01

申请号：US17661971

申请日：2022-05-04

Applicant: Oryzon Genomics, S.A.

Inventor： Mark D. DEMARIO ,  Tamara MAES ,  William E. PIERCEALL ,  Fiona MACK ,  Serena LUNARDI

IPC: A61K31/135 ,  A61K31/12 ,  A61K31/19 ,  A61K31/282 ,  A61K31/337 ,  A61K31/4045 ,  A61K31/4745 ,  A61K31/475 ,  A61K31/495 ,  A61K31/519 ,  A61K31/555 ,  A61K31/704 ,  A61K31/7068 ,  A61K31/167 ,  A61K31/404 ,  A61K31/4402 ,  A61K31/4545 ,  A61K31/47 ,  A61K31/496 ,  A61K31/52 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/551 ,  A61K31/635

Abstract: The instant invention relates to therapeutic combinations of LSD1 inhibitors and one or more other active pharmaceutical ingredient(s) or pharmaceutically acceptable salts thereof. The combinations are particularly useful for treating neoplastic diseases, such as cancer, particularly small cell lung cancer (SCLC).

公开(公告)号：US20190085372A1

公开(公告)日：2019-03-21

申请号：US16085024

申请日：2017-03-16

Applicant: Oryzon Genomics S.A.

Inventor： Elena CARCELLER GONZÁLEZ ,  Tamara MAES ,  Cristina MASCARO CRUSAT ,  Alberto ORTEGA MUN0Z

IPC: C12Q1/26 ,  C07D495/04

Abstract: The invention relates to methods to determine KDM1A target engagement and chemoprobes useful therefor. In particular, the invention relates to non-peptidic KDM1A chemoprobes carrying a tag or label that can be used to assess KDM1A target engagement in cells and tissues. These chemoprobes can also be used to identify KDM1A interacting factors and analyze expression levels of KDM1A.

公开(公告)号：US20160081947A1

公开(公告)日：2016-03-24

申请号：US14675990

申请日：2015-04-01

Applicant: ORYZON GENOMICS S.A.

Inventor： Tamara MAES ,  Carlos BUESA ARJOL

IPC: A61K31/135 ,  A61K31/495 ,  A61K31/165

CPC classification number: A61K31/135 ,  A61K31/00 ,  A61K31/13 ,  A61K31/165 ,  A61K31/495 ,  C07C237/20 ,  C07D295/14

Abstract: The invention relates to methods and compositions for the treatment or prevention of protein conformation disorders. In particular, the invention relates to an LSD1 inhibitor for use in treating or preventing a protein conformation disorder, such as, e.g., Huntington Disease.

Abstract translation: 本发明涉及用于治疗或预防蛋白质构象障碍的方法和组合物。 特别地，本发明涉及用于治疗或预防蛋白质构象障碍（例如亨廷顿病）的LSD1抑制剂。

公开(公告)号：US20250073232A1

公开(公告)日：2025-03-06

申请号：US18554241

申请日：2022-03-21

Applicant: ORYZON GENOMICS, S.A.

Inventor： Tamara MAES ,  Natalia SACILOTTO

IPC: A61K31/497 ,  A61K31/136 ,  A61P35/02

Abstract: The instant invention relates to combinations of LSD1 inhibitors (or pharmaceutically acceptable salts thereof) and gilteritinib (or a pharmaceutically acceptable salt thereof). The combinations are particularly useful for treating myeloid cancers, such as acute myeloid leukemia or myelodysplastic syndrome.

公开(公告)号：US20200323828A1

公开(公告)日：2020-10-15

申请号：US16635704

申请日：2018-08-03

Applicant: Oryzon Genomics, S.A.

Inventor： Tamara MAES ,  David ROTLLANT POZO ,  Christian GRIÑÁN FERRE ,  Mercè PALLÀS LLIBERIA ,  Roser NADAL ALEMANY ,  Antonio ARMARIO GARCÍA

IPC: A61K31/4245 ,  A61P25/18

Abstract: Provided herein are methods for treating behavior alterations using KDM1A inhibitors, particularly 5-((((1R,2S)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine.

公开(公告)号：US20240277673A1

公开(公告)日：2024-08-22

申请号：US18451897

申请日：2023-08-18

Applicant: Oryzon Genomics, S.A.

Inventor： Tamara MAES ,  David ROTLLANT POZO ,  Christian GRIÑÁN FERRE ,  Mercè PALLÀSLLIBERIA ,  Roser NADAL ALEMANY ,  Antonio ARMARIO GARCÍA

IPC: A61K31/4245 ,  A61K9/00 ,  A61P25/18

CPC classification number: A61K31/4245 ,  A61P25/18 ,  A61K9/0053

Abstract: Provided herein are methods for treating behavior alterations using KDM1A inhibitors, particularly 5-((((1R,2S)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine.

公开(公告)号：US20220331265A1

公开(公告)日：2022-10-20

申请号：US17531370

申请日：2021-11-19

Applicant: Oryzon Genomics S.A.

Inventor： Filippo CICERI ,  Serena LUNARDI ,  Tamara MAES ,  Cristina MASCARO CRUSAT ,  Inigo TIRAPU FERNANDEZ DE LA CUESTA

IPC: A61K31/015 ,  A61K31/12 ,  A61K31/282 ,  A61K31/337 ,  A61K31/4045 ,  A61K31/4745 ,  A61K31/475 ,  A61K31/519 ,  A61K31/555 ,  A61K31/704 ,  A61K31/7068 ,  A61K31/19 ,  A61P35/00 ,  A61K31/135 ,  A61K31/17 ,  A61K31/203 ,  A61K31/496 ,  A61K33/36 ,  A61P35/02 ,  A61K31/64

Abstract: The instant invention relates to combinations of the compound of formula (I) or pharmaceutically acceptable salts thereof with other active pharmaceutical ingredients (I), pharmaceutical compositions comprising them, and their use as medicaments, particularly for the treatment of hematological malignancies.

公开(公告)号：US20190083417A1

公开(公告)日：2019-03-21

申请号：US16084683

申请日：2017-03-13

Applicant: Oryzon Genomics S.A.

Inventor： Filippo CICERI ,  Serena LUNARDI ,  Tamara MAES ,  Cristina MASCARO CRUSAT ,  Inigo TIRAPU FERNANDEZ DE LA CUEST

IPC: A61K31/015 ,  A61K31/12 ,  A61P35/02 ,  A61K31/135 ,  A61K31/17 ,  A61K31/203 ,  A61K31/282 ,  A61K31/337 ,  A61K31/4045 ,  A61K31/4745 ,  A61K31/475 ,  A61K31/496 ,  A61K31/519 ,  A61K31/555 ,  A61K31/704 ,  A61K31/7068 ,  A61K33/36 ,  A61K31/64

Abstract: The instant invention relates to combinations of the compound of formula (I) or pharmaceutically acceptable salts thereof with other active pharmaceutical ingredients pharmaceutical compositions comprising them, and their use as medicaments, particularly for the treatment of hematological malignancies.

公开(公告)号：US20220389478A1

公开(公告)日：2022-12-08

申请号：US17644604

申请日：2021-12-16

Applicant: Oryzon Genomics S.A.

Inventor： Elena CARCELLER GONZÁLEZ ,  Tamara MAES ,  Cristina MASCARO CRUSAT ,  Alberto ORTEGA MUÑOZ

IPC: C12Q1/26 ,  C07D495/04 ,  G01N33/58

Abstract: The invention relates to methods to determine KDM1A target engagement and chemoprobes useful therefor. In particular, the invention relates to non-peptidic KDM1A chemoprobes carrying a tag or label that can be used to assess KDM1A target engagement in cells and tissues. These chemoprobes can also be used to identify KDM1A interacting factors and analyze expression levels of KDM1A.

公开(公告)号：US20190256930A1

公开(公告)日：2019-08-22

申请号：US16346915

申请日：2017-11-02

Applicant: ORYZON GENOMICS, S.A.

Inventor： Maria Isabel ARÉVALO SÁNCHEZ ,  Serena LUNARDI ,  Tamara MAES ,  Cristina MASCARO CRUSAT

IPC: C12Q1/6886 ,  A61P35/02 ,  A61K31/135

Abstract: The present invention relates to methods for monitoring the response to treatment with an LSD1 inhibitor in a subject suffering from leukemia. The present invention also provides methods for the identification of a responding subject to treatment with an LSD1 inhibitor. Also methods of determining whether a proliferative diseased cell is responsive to treatment with an LSD1 inhibitor are provided. The methods comprise determining the level of one or more of markers in a sample, wherein an increased level of one or more of said markers compared to a control indicates responsiveness to the LSD1 inhibitor. Methods of treatment of patients with the LSD1 inhibitor, wherein the patients are identified in accordance with the present invention to be responders are also subject of the present invention. LSD1 inhibitors for use in the treatment of this patient group are provided.